查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1606458

胃輕癱治療市場，按藥物類別、類型、給藥途徑、疾病適應症、配銷通路、國家和地區 - 2024-2032 年行業分析、市場規模、市場佔有率和預測

Gastroparesis Treatment Market, By Drug Class, By Type, By Route of Administration, By Disease Indication, By Distribution Channel, By Country, and By Region - Industry Analysis, Market Size, Market Share & Forecast from 2024-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告要點

2023年胃輕癱治療市場規模為63.9043億美元，2024年至2032年複合年成長率為4.77%。

胃輕癱治療市場-市場動態

全球糖尿病盛行率上升推動市場需求

由於糖尿病是胃輕癱的主要原因，全球糖尿病病例的增加刺激了對胃輕癱治療的需求。國際糖尿病聯盟報告稱，2021年有5.37億成年人患有糖尿病，預計到2030年這一數字將增至6.43億。增加支持了胃輕癱治療的需求。然而，目前的胃輕癱治療側重於症狀管理而不是治癒病情，這限制了有效性並導致患者不滿意。這可能會阻礙未來幾年的市場成長。相反，正在進行的對胃輕癱根本原因的研究、提高認知活動以及改進早期檢測的診斷工具的進步預計將在預測期內為全球胃輕癱治療市場提供巨大的成長機會。

胃輕癱治療市場 - 主要見解

根據我們的研究分析師分享的分析，預計全球市場在預測期內（2024-2032 年）每年將以 4.77% 左右的複合年成長率成長

根據藥物類別細分，預計促動力藥物將在 2023 年呈現最大市場佔有率

從類型細分來看，處方藥是2023年的主導細分市場

依給藥途徑細分，2023年口服為主導類型

依疾病適應症細分，2023年糖尿病胃輕癱為主導細分

從配銷通路細分來看，醫院藥局是2023年的主導細分市場

按地區分類，北美胃輕癱治療市場是 2023 年的主要收入來源

胃輕癱治療市場-細分分析：

全球胃輕癱治療市場根據藥物類別、類型、給藥途徑、疾病適應症、配銷通路和地區進行細分。

依藥物類別，市場分為四大類：止吐藥、促動力藥、質子幫浦抑制劑等。促胃動力藥物對於胃輕癱的治療至關重要，因為它們可以增強胃肌收縮，減輕噁心等症狀並改善消化。它們的功效不僅限於胃輕癱，研究顯示它們還可以幫助重症患者接受腸內營養，減少餵食不耐受。

全球胃輕癱治療市場依類型分為兩大類：處方藥和非處方藥。在預測期內，處方藥產業可能會主導市場。這是由於胃輕癱盛行率不斷上升以及對有效治療的需求不斷成長。處方藥通常更有效，並且專門針對複雜的病情而設計，這推動了它們在醫療保健提供者和患者中的採用。

胃輕癱治療市場 - 地理洞察

從地理來看，該市場廣泛分佈於北美、拉丁美洲、歐洲、亞太地區、中東和非洲地區。這些區域根據開展業務的國家進一步分類。

胃輕癱治療市場-競爭格局：

胃輕癱盛行率的日益增加正在形成一個專注於創新治療方案的競爭格局。公司正在優先考慮研發以引入先進的療法，包括促動力劑和飲食管理解決方案。與醫療保健專業人員和研究機構的合作可提高治療效果並促進最新臨床實踐的採用。此外，透過教育活動提高認知對於改善早期診斷和患者對治療的依從性至關重要。個人化醫療的趨勢也正在興起，允許客製化治療計劃，更好地滿足個別患者的需求。

最新進展：

2024 年 6 月，專注於胃腸道治療的生物製藥公司 Renexxion Ireland Limited 的那羅那必利研究性新藥申請獲得 FDA 批准。這種口服藥物針對胃輕癱，這是一種導致胃排空延遲並伴隨噁心和嘔吐等症狀的疾病，影響了美國、歐洲和澳洲的數百萬人。

目錄

第1章：胃輕癱治療市場概述

  • 研究範圍
  • 市場預估年份

第 2 章：執行摘要

  • 市場片段
    • 按藥物類別分類的胃輕癱治療市場片段
    • 按類型分類的胃輕癱治療市場片段
    • 依給藥途徑分類的胃輕癱治療市場片段
    • 按疾病適應症分類的胃輕癱治療市場片段
    • 按配銷通路分類的胃輕癱治療市場片段
    • 按國家/地區分類的胃輕癱治療市場片段
    • 按地區分類的胃輕癱治療市場片段
  • 競爭洞察

第 3 章：胃輕癱治療主要市場趨勢

  • 胃輕癱治療市場促進因素
    • 市場促進因素的影響分析
  • 胃輕癱治療市場限制
    • 市場限制影響分析
  • 胃輕癱治療市場機會
  • 胃輕癱治療市場未來趨勢

第 4 章：胃輕癱治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第 5 章：胃輕癱治療市場：地緣政治緊張局勢升級的影響

  • COVID-19 大流行的影響
  • 俄羅斯-烏克蘭戰爭的影響
  • 中東衝突的影響

第 6 章：胃輕癱治療市場格局

  • 2023 年胃輕癱治療市佔分析
  • 按主要製造商分類的故障數據
    • 既有參與者分析
    • 新興參與者分析

第 7 章：胃輕癱治療市場 - 依藥物類別

  • 概述
    • 按藥物類別分類的細分市場佔有率分析
    • 止吐藥
    • 促動力劑
    • 質子幫浦抑制劑
    • 其他

第 8 章：胃輕癱治療市場 - 按類型

  • 概述
    • 按類型分類的細分市場佔有率分析
    • 處方藥
    • 非處方藥

第 9 章：胃輕癱治療市場 - 按給藥途徑

  • 概述
    • 按給藥途徑分類的細分市場佔有率分析
    • 鼻腔
    • 注射劑
    • 口服

第 10 章：胃輕癱治療市場 - 依疾病適應症

  • 概述
    • 按疾病適應症分類的細分市場佔有率分析
    • 特發性胃輕癱
    • 糖尿病胃輕癱
    • 術後胃輕癱

第 11 章：胃輕癱治療市場 - 按配銷通路

  • 概述
    • 按配銷通路分類的細分市場佔有率分析
    • 網路藥局
    • 零售藥局
    • 醫院藥房

第 12 章：胃輕癱治療市場 - 依地理位置

  • 介紹
    • 按地理位置分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美胃輕癱治療主要製造商
    • 北美市場規模和預測（按國家）
    • 北美市場規模和預測（按藥物類別）
    • 北美市場規模和預測（按類型）
    • 北美市場規模與預測（按管理途徑）
    • 北美市場規模與預測（按疾病適應症）
    • 北美市場規模和預測（按配銷通路）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲胃輕癱治療主要製造商
    • 歐洲市場規模和預測（按國家）
    • 歐洲市場規模和預測（按藥物類別）
    • 歐洲市場規模與預測（按類型）
    • 歐洲市場規模與預測（按管理途徑）
    • 歐洲市場規模與預測（按疾病適應症）
    • 歐洲市場規模和預測（按配銷通路）
    • 德國
    • 義大利
    • 英國
    • 法國
    • 俄羅斯
    • 荷蘭
    • 瑞典
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區胃輕癱治療主要製造商
    • 亞太地區市場規模與預測（按國家）
    • 亞太地區市場規模和預測（按藥物類別）
    • 亞太地區市場規模與預測（按類型）
    • 亞太地區市場規模與預測（依管理途徑）
    • 亞太地區市場規模與預測（依疾病適應症）
    • 亞太地區市場規模和預測（按配銷通路）
    • 印度
    • 中國
    • 日本
    • 韓國
    • 澳洲
    • 泰國
    • 印尼
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲
    • 概述
    • 拉丁美洲胃輕癱治療主要製造商
    • 拉丁美洲市場規模與預測（按國家）
    • 拉丁美洲市場規模與預測（按藥物類別）
    • 拉丁美洲市場規模與預測（按類型）
    • 拉丁美洲市場規模與預測（按管理途徑）
    • 拉丁美洲市場規模與預測（按疾病適應症）
    • 拉丁美洲市場規模和預測（按配銷通路）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲胃輕癱治療主要製造商
    • 中東和非洲市場規模及預測（按國家）
    • 中東和非洲市場規模及預測（按藥物類別）
    • 中東和非洲市場規模及預測（按類型）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（依疾病指示）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 的其餘部分

第 13 章：主要供應商分析-胃輕癱治療產業

  • 競爭儀表板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • Medtronic plc
    • Abbott Laboratories
    • Salix Pharmaceuticals, Inc.
    • Kimberly-Clark Corporation
    • CR Bard, Inc
    • Boston Scientific Corporation
    • Janssen Global Services LLC
    • Alfa Wassermann SPA
    • AbbVie Inc.
    • Evoke Pharma
    • Cardinal Health, Inc.
    • Rhythm Pharmaceuticals, Inc.
    • GlaxoSmithKline Plc
    • Bausch Health
    • Neurogastrx, Inc.
    • Theravance Biopharma
    • AstraZeneca Plc
    • Cipla Limited
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Limited
    • The Takeda Pharmaceutical Company Ltd.
    • Processa Pharmaceuticals, Inc.
    • Vanda Pharmaceuticals, Inc.
    • Otsuka Holdings Co. Ltd.
    • ANI Pharmaceuticals, Inc.
    • CinDome Pharma, Inc.
    • PTC Therapeutics
    • Ironwood Pharmaceuticals, Inc.
    • Others

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4173

REPORT HIGHLIGHT

Gastroparesis treatment market size was valued at USD 6,390.43 Million in 2023, expanding at a CAGR of 4.77% from 2024 to 2032.

Gastroparesis is a condition in which the stomach's ability to empty is delayed due to partial paralysis. This causes food to remain in the stomach longer than normal. The gastroparesis treatment focuses on managing delayed stomach emptying, aiming to alleviate symptoms like nausea, vomiting, and bloating. Primary approaches include prokinetic agents that enhance gastric motility, antiemetics to control nausea, and dietary modifications for symptom relief. For severe cases, gastric electrical stimulation may be used. As gastroparesis is commonly linked to diabetes and is often underdiagnosed, early diagnosis and targeted treatments are essential for effective management.

Gastroparesis Treatment Market- Market Dynamics

Increasing prevalence of diabetes globally to propel market demand

As diabetes is a major cause of gastroparesis, the global increase in diabetes cases fuels demand for gastroparesis treatments. The International Diabetes Federation reports that 537 million adults were living with diabetes in 2021, with numbers projected to rise to 643 million by 2030. Besides, as gastroparesis is more common in older adults, the global increase in the aging population supports demand for gastroparesis treatment. However, current gastroparesis treatments focus on symptom management rather than curing the condition, which limits effectiveness and leads to patient dissatisfaction. This may hamper the market growth in the coming years. On the contrary, ongoing research into the underlying causes of gastroparesis, increasing awareness campaigns, and advancements in diagnostic tools to improve early detection are all expected to provide massive growth opportunities for the global gastroparesis treatment market during the forecast period.

Gastroparesis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 4.77% over the forecast period (2024-2032)

Based on drug class segmentation, prokinetic drugs was predicted to show maximum market share in the year 2023

Based on type segmentation, prescription drugs was the leading segment in 2023

Based on route of administration segmentation, oral was the leading type in 2023

Based on disease indication segmentation, diabetes gastroparesis was the leading segment in 2023

Based on distribution channel segmentation, hospital pharmacies was the leading segment in 2023

On the basis of region, the North America gastroparesis treatment market was the leading revenue generator in 2023

Gastroparesis Treatment Market- Segmentation Analysis:

The Global Gastroparesis Treatment Market is segmented on the basis of Drug Class, Type, Route of Administration, Disease Indication, Distribution Channel, and Region.

The market is divided into four categories based on drug class: antiemetic drugs, prokinetic agents, proton pump inhibitors, and others. Prokinetic agents are crucial in the treatment of gastroparesis as they enhance stomach muscle contractions, alleviating symptoms like nausea and improving digestion. Their effectiveness extends beyond gastroparesis and studies have shown that they also help critical patients receiving enteral nutrition, reducing feeding intolerance.

The global gastroparesis treatment market is divided into two categories based on type: prescription drugs and over-the-counter drugs. The prescription drugs sector is likely to dominate the market during the forecast period. This is due to the rising prevalence of gastroparesis and the growing demand for effective treatments. Prescription medications are often more potent and specifically tailored to address the complexities of the condition, which drives their adoption among healthcare providers and patients.

Gastroparesis Treatment Market- Geographical Insights

Geographically, this market is widespread into the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided as per the nations bringing business.

Gastroparesis Treatment Market- Competitive Landscape:

The increasing prevalence of gastroparesis is creating a competitive landscape focused on innovative treatment options. Companies are prioritizing research and development to introduce advanced therapies, including prokinetic agents and dietary management solutions. Collaborations with healthcare professionals and research institutions enhance treatment effectiveness and foster the adoption of the latest clinical practices. Additionally, raising awareness through educational initiatives is essential for improving early diagnosis and patient adherence to treatments. The trend towards personalized medicine is also emerging, allowing for tailored treatment plans that better address individual patient needs.

Recent Developments:

In June 2024, Renexxion Ireland Limited, a biopharmaceutical company focused on gastrointestinal treatments, has gained FDA approval for its Investigational New Drug application for naronapride. This oral drug targets gastroparesis, a disorder causing delayed stomach emptying with symptoms like nausea and vomiting, affecting millions in the U.S., Europe, and Australia.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL GASTROPARESIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Medtronic plc
  • Abbott Laboratories
  • Salix Pharmaceuticals, Inc.
  • Kimberly-Clark Corporation
  • C. R. Bard, Inc
  • Boston Scientific Corporation
  • Janssen Global Services LLC
  • Alfa Wassermann SPA
  • AbbVie Inc.
  • Evoke Pharma
  • Cardinal Health, Inc.
  • Rhythm Pharmaceuticals, Inc.
  • GlaxoSmithKline Plc
  • Bausch Health
  • Neurogastrx, Inc.
  • Theravance Biopharma
  • AstraZeneca Plc
  • Cipla Limited
  • Pfizer, Inc.
  • Teva Pharmaceutical Industries Limited
  • The Takeda Pharmaceutical Company Ltd.
  • Processa Pharmaceuticals, Inc.
  • Vanda Pharmaceuticals, Inc.
  • Otsuka Holdings Co. Ltd.
  • ANI Pharmaceuticals, Inc.
  • CinDome Pharma, Inc.
  • PTC Therapeutics
  • Ironwood Pharmaceuticals, Inc.
  • Others

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DRUG CLASS- MARKET ANALYSIS, 2019 - 2032

  • Antiemetic Drugs
  • Prokinetic Agents
  • Proton Pump Inhibitors
  • Others

GLOBAL GASTROPARESIS TREATMENT MARKET, BY TYPE- MARKET ANALYSIS, 2019 - 2032

  • Prescription Drugs
  • Over-the-Counter Drugs

GLOBAL GASTROPARESIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Nasal
  • Injectables
  • Oral

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DISEASE INDIATION- MARKET ANALYSIS, 2019 - 2032

  • Idiopathic Gastroparesis
  • Diabetes Gastroparesis
  • Post-surgical Gastroparesis

GLOBAL GASTROPARESIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Online Pharmacies
  • Retail Pharmacies
  • Hospital Pharmacies

GLOBAL GASTROPARESIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • The U.S.
  • Canada
  • Europe
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom
  • Russia
  • Netherlands
  • Sweden
  • Poland
  • Rest of Europe
  • Asia Pacific
  • India
  • China
  • South Korea
  • Japan
  • Australia
  • Thailand
  • Indonesia
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • United Arab Emirates
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Gastroparesis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Gastroparesis Treatment Market Snippet by Drug Class
    • 2.1.2. Gastroparesis Treatment Market Snippet by Type
    • 2.1.3. Gastroparesis Treatment Market Snippet by Route of Administration
    • 2.1.4. Gastroparesis Treatment Market Snippet by Disease Indication
    • 2.1.5. Gastroparesis Treatment Market Snippet by Distribution Channel
    • 2.1.6. Gastroparesis Treatment Market Snippet by Country
    • 2.1.7. Gastroparesis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Gastroparesis Treatment Key Market Trends

  • 3.1. Gastroparesis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Gastroparesis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Gastroparesis Treatment Market Opportunities
  • 3.4. Gastroparesis Treatment Market Future Trends

4. Gastroparesis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Gastroparesis Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Gastroparesis Treatment Market Landscape

  • 6.1. Gastroparesis Treatment Market Share Analysis, 2023
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Gastroparesis Treatment Market - By Drug Class

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Drug Class, 2023 & 2032 (%)
    • 7.1.2. Antiemetic Drugs
    • 7.1.3. Prokinetic Agents
    • 7.1.4. Proton Pump Inhibitors
    • 7.1.5. Others

8. Gastroparesis Treatment Market - By Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Type, 2023 & 2032 (%)
    • 8.1.2. Prescription Drugs
    • 8.1.3. Over-the-Counter Drugs

9. Gastroparesis Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2023 & 2032 (%)
    • 9.1.2. Nasal
    • 9.1.3. Injectables
    • 9.1.4. Oral

10. Gastroparesis Treatment Market - By Disease Indication

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Disease Indication, 2023 & 2032 (%)
    • 10.1.2. Idiopathic Gastroparesis
    • 10.1.3. Diabetes Gastroparesis
    • 10.1.4. Post-surgical Gastroparesis

11. Gastroparesis Treatment Market - By Distribution Channel

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By Distribution Channel, 2023 & 2032 (%)
    • 11.1.2. Online Pharmacies
    • 11.1.3. Retail Pharmacies
    • 11.1.4. Hospital Pharmacies

12. Gastroparesis Treatment Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2023 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Gastroparesis Treatment Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Gastroparesis Treatment Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.10. Italy
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. Italy Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.10.4. Italy Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. Italy Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.10.7. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.11. United Kingdom
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. United Kingdom Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.11.4. United Kingdom Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. United Kingdom Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. United Kingdom Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.11.7. United Kingdom Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.12. France
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. France Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.12.4. France Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. France Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.12.7. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.13. Russia
      • 12.3.13.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.2. Russia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.13.3. Russia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Russia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.14. Netherlands
      • 12.3.14.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.2. Netherlands Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.14.3. Netherlands Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.5. Netherlands Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.14.6. Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.2. Sweden Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.16. Poland
      • 12.3.16.1. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.2. Poland Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.16.3. Poland Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Poland Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.17. Rest of Europe
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Rest of the Europe Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Rest of the Europe Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Rest of the Europe Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Gastroparesis Treatment Key Manufacturers in Asia Pacific
    • 12.4.3. Asia Pacific Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. Asia Pacific Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.4.5. Asia Pacific Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.4.6. Asia Pacific Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. Asia Pacific Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.4.8. Asia Pacific Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.9. India
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. India Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.9.4. India Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. India Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.9.7. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.10. China
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. China Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.10.4. China Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. China Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.10.7. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.14. Thailand
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Thailand Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Thailand Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Thailand Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.15. Indonesia
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Indonesia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Indonesia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Indonesia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.5. Latin America
    • 12.5.1. Overview
    • 12.5.2. Gastroparesis Treatment Key Manufacturers in Latin America
    • 12.5.3. Latin America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. Latin America Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.5.5. Latin America Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.5.6. Latin America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. Latin America Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.5.8. Latin America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Gastroparesis Treatment Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Drug Class, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Disease Indication, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Gastroparesis Treatment Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. Medtronic plc
    • 13.2.2. Abbott Laboratories
    • 13.2.3. Salix Pharmaceuticals, Inc.
    • 13.2.4. Kimberly-Clark Corporation
    • 13.2.5. C. R. Bard, Inc
    • 13.2.6. Boston Scientific Corporation
    • 13.2.7. Janssen Global Services LLC
    • 13.2.8. Alfa Wassermann SPA
    • 13.2.9. AbbVie Inc.
    • 13.2.10. Evoke Pharma
    • 13.2.11. Cardinal Health, Inc.
    • 13.2.12. Rhythm Pharmaceuticals, Inc.
    • 13.2.13. GlaxoSmithKline Plc
    • 13.2.14. Bausch Health
    • 13.2.15. Neurogastrx, Inc.
    • 13.2.16. Theravance Biopharma
    • 13.2.17. AstraZeneca Plc
    • 13.2.18. Cipla Limited
    • 13.2.19. Pfizer, Inc.
    • 13.2.20. Teva Pharmaceutical Industries Limited
    • 13.2.21. The Takeda Pharmaceutical Company Ltd.
    • 13.2.22. Processa Pharmaceuticals, Inc.
    • 13.2.23. Vanda Pharmaceuticals, Inc.
    • 13.2.24. Otsuka Holdings Co. Ltd.
    • 13.2.25. ANI Pharmaceuticals, Inc.
    • 13.2.26. CinDome Pharma, Inc.
    • 13.2.27. PTC Therapeutics
    • 13.2.28. Ironwood Pharmaceuticals, Inc.
    • 13.2.29. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us